National Research Corporation logo
National Research Corporation NRC
$ 17.13 -1.32%

Annual report 2025
added 03-05-2026

report update icon

National Research Corporation Income Statement 2011-2026 | NRC

Annual Income Statement National Research Corporation

2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011

Market Cap

315 M 334 M 1.01 B 1.14 B 1.06 B 1.13 B 1.72 B 1.06 B 899 M 417 M 365 M 336 M 374 M - -

Shares

22.4 M 23.7 M 24.5 M 24.9 M 25.4 M 25.2 M 24.8 M 27.1 M 24.3 M 24.2 M 24.2 M 24.2 M 24.1 M - -

Historical Prices

14.1 14.1 41.1 45.7 41.6 45.1 66.8 38.3 35.5 16.2 13.4 12.1 13.1 - -

Net Income

11.6 M 24.8 M 31 M 31.8 M 37.5 M 37.3 M 32.4 M 30 M 22.9 M 20.5 M 17.6 M 18.2 M 15.5 M 15.1 M 11.6 M

Revenue

137 M 143 M 149 M 152 M 148 M 133 M 128 M 120 M 118 M 109 M 102 M 98.8 M 92.6 M 86.4 M 75.8 M

Gross Profit

- - - - - - 81.5 M 72.1 M 68.5 M 63.8 M 57.7 M 57.1 M 53.7 M 51 M 47.1 M

Operating Income

22.6 M 35.2 M 40 M 46.5 M 50.3 M 42.7 M 43 M 35.3 M 34.2 M 31.2 M 26.4 M 28.3 M 24.8 M 22.7 M 18.7 M

Interest Expense

-95 K -34 K -41 K 1.21 M 1.67 M 1.81 M 2.09 M 1.51 M 82 K 190 K 220 K 305 K 397 K 541 K 629 K

EBITDA

30.2 M 41.2 M 45.9 M 46.7 M 50.6 M 43 M 48.6 M 40.7 M 38.8 M 35.4 M 30.6 M 32.1 M 28.5 M 27.4 M 23.8 M

Operating Expenses

- - - - - - 38.5 M 36.8 M 34.3 M 32.6 M 31.3 M 28.8 M 28.9 M 28.2 M 28.4 M

General and Administrative Expenses

54.8 M 44.9 M 46.6 M 42.7 M 39 M 34.4 M 33 M 31.4 M 29.7 M 28.4 M 27.2 M 25 M 25.2 M 23.5 M 23.3 M

All numbers in USD currency

Quarterly Income Statement National Research Corporation

2025-Q3 2025-Q2 2025-Q1 2024-Q4 2024-Q3 2024-Q2 2024-Q1 2023-Q4 2023-Q3 2023-Q2 2023-Q1 2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

22.1 M 22.7 M 23 M 23.1 M 23.7 M 23.9 M 23.9 M 24.2 M 24.6 M 24.6 M 24.6 M 24.6 M 24.7 M 25.1 M 25.3 M 25.4 M 25.4 M 25.4 M 25.4 M 25.4 M 25.2 M 25.1 M 25 M 24.9 M 24.8 M 24.8 M 24.8 M 24.8 M 24.8 M 24.8 M 24.8 M 20.9 M 20.9 M 20.9 M - - - - - - - - - - - - - - - - 6.89 M 6.87 M 6.79 M 6.75 M 6.72 M 6.72 M 6.68 M 6.66 M 6.65 M

Net Income

4.12 M -106 K 5.79 M - 5.69 M 6.18 M 6.36 M - 7.88 M 7.27 M 6.96 M - 8.3 M 8.32 M 8.54 M - 9.66 M 8.94 M 9.23 M - 9.58 M 7.72 M 11.8 M - 8.12 M 7.39 M 8.2 M - 6.99 M 7.95 M 7.31 M - 4.15 M 5.75 M 6.52 M - 4.73 M 4.56 M 5.51 M - 4.14 M 4.06 M 3.48 M - 4.55 M 4.05 M 5.45 M - 3.81 M 3.43 M 4.47 M - 3.58 M 3.94 M 3.85 M - 2.65 M 2.33 M 3.46 M

Revenue

34.6 M 34 M 33.6 M - 35.8 M 35 M 35.3 M - 37.9 M 36.2 M 36.5 M - 37.7 M 37.3 M 38.4 M - 37.8 M 36.4 M 35.5 M - 33.5 M 31.2 M 33.9 M - 32.5 M 31.4 M 31.5 M - 30 M 28 M 31 M - 29 M 28.4 M 30.3 M - 27 M 26.1 M 27.9 M - 25.2 M 24.5 M 26.3 M - 23.7 M 24 M 26 M - 22.4 M 22.4 M 24.9 M - 21.4 M 20.6 M 22.4 M - 18.5 M 18.3 M 19.8 M

Operating Income

7.74 M 1.59 M 8.6 M - 7.98 M 8.86 M 8.76 M - 9.96 M 9.36 M 9.02 M - 11.1 M 11.5 M 11.7 M - 13.1 M 12.2 M 12 M - 12 M 9.28 M 11.2 M - 10.2 M 10.1 M 10.7 M - 9.17 M 7.76 M 8.96 M - 7.12 M 8.45 M 9.98 M - 7.34 M 7.02 M 8.01 M - 6.55 M 6.36 M 5.83 M - 7.16 M 6.32 M 8.4 M - 6.03 M 5.53 M 7.22 M - 5.65 M 5.22 M 6.08 M - 4.19 M 3.83 M 5.7 M

Interest Expense

1.46 M 1.03 M 899 K - 706 K 555 K 605 K - -12 K -2 K 241 K - 288 K 318 K 317 K - 413 K 423 K 432 K - 451 K 450 K 465 K - 510 K 533 K 570 K - 544 K 439 K 8 K - 18 K 23 K 27 K - 38 K 36 K 85 K - 52 K 57 K 63 K - 76 K 78 K 81 K - 91 K 101 K 117 K - 134 K 140 K 142 K - 155 K 156 K 169 K

EBITDA

9.93 M 3.33 M 10.1 M - 9.53 M 10.4 M 10.2 M - 11.5 M 10.9 M 10.4 M - 12.4 M 12.8 M 13 M - 13.1 M 12.2 M 12 M - 13.9 M 10.7 M 12.6 M - 11.6 M 11.6 M 12.1 M - 10.6 M 9.08 M 10.2 M - 8.25 M 9.59 M 11.1 M - 8.42 M 8.11 M 8.97 M - 7.62 M 7.39 M 6.84 M - 8.11 M 7.24 M 9.34 M - 6.94 M 6.46 M 8.17 M - 6.8 M 6.43 M 7.32 M - 5.51 M 5.07 M 6.94 M

Operating Expenses

- - - - - - - - - - - - - - - - - - - - - - - - - 21.3 M 20.8 M - 20.8 M 20.3 M 22.1 M - 21.8 M 20 M 20.3 M - 19.7 M 19.1 M 19.9 M - 18.7 M 18.1 M 20.4 M - 16.5 M 17.7 M 17.6 M - 16.4 M 16.8 M 17.7 M - 15.7 M 15.4 M 16.3 M - 14.4 M 14.5 M 14.1 M

General and Administrative Expenses

12.3 M 17.7 M 10.4 M - 11 M 11.2 M 11.2 M - 11.8 M 12 M 11.8 M - 10.8 M 10.7 M 10.6 M - 9.52 M 10 M 9.52 M - 7.95 M 8.85 M 8.75 M - 8.71 M 8.32 M 7.71 M - 7.68 M 7.94 M 7.87 M - 8.43 M 6.9 M 6.69 M - 7.14 M 7.27 M 7.36 M - 6.62 M 6.64 M 7.63 M - 5.8 M 5.98 M 6.37 M - 6.02 M 6.39 M 6.49 M - 5.82 M 5.57 M 6.15 M - 5.57 M 5.99 M 6.09 M

All numbers in USD currency

The income statement is one of the three key financial reports of a company National Research Corporation (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:

  • How much revenue the company earned
  • How much it spent on production, personnel, marketing, taxes, etc.
  • What profit remained in the end

Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.

Features
  • The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
  • Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
  • A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.

Reports on the profits and losses of other stocks in the Diagnostics research industry

Issuer Price % 24h Market Cap Country
Agilent Technologies Agilent Technologies
A
$ 110.24 -2.86 % $ 33.5 B usaUSA
Centogene N.V. Centogene N.V.
CNTG
- -6.23 % $ 30.6 M germanyGermany
Waters Corporation Waters Corporation
WAT
$ 289.16 -3.79 % $ 17.2 B usaUSA
Exagen Exagen
XGN
$ 2.68 -3.94 % $ 57.8 M usaUSA
Enzo Biochem Enzo Biochem
ENZ
- -8.98 % $ 14.8 K usaUSA
Exact Sciences Corporation Exact Sciences Corporation
EXAS
- - $ 19.8 B usaUSA
Akumin Akumin
AKU
- -17.87 % $ 25.9 M canadaCanada
Burning Rock Biotech Limited Burning Rock Biotech Limited
BNR
$ 16.36 -11.57 % $ 176 M chinaChina
Sotera Health Company Sotera Health Company
SHC
$ 13.13 -3.03 % $ 3.73 B usaUSA
Check-Cap Ltd. Check-Cap Ltd.
CHEK
- - $ 9.42 M israelIsrael
Heska Corporation Heska Corporation
HSKA
- - $ 1.31 B usaUSA
Oxford Immunotec Global PLC Oxford Immunotec Global PLC
OXFD
- - $ 562 M britainBritain
BioNano Genomics BioNano Genomics
BNGO
$ 1.16 0.87 % $ 6.32 M usaUSA
DermTech DermTech
DMTK
- -11.32 % $ 2.94 M usaUSA
Aspira Women's Health Aspira Women's Health
AWH
- -6.19 % $ 10.5 M usaUSA
DexCom DexCom
DXCM
$ 62.25 -5.81 % $ 24.3 B usaUSA
Accelerate Diagnostics Accelerate Diagnostics
AXDX
- -61.36 % $ 2.46 M usaUSA
Global Cord Blood Corporation Global Cord Blood Corporation
CO
- - $ 399 M chinaChina
Fluidigm Corporation Fluidigm Corporation
FLDM
- 1.08 % $ 308 M usaUSA
Genetic Technologies Limited Genetic Technologies Limited
GENE
- - $ 7.1 B australiaAustralia
Genetron Holdings Limited Genetron Holdings Limited
GTH
- 0.12 % $ 80.1 M chinaChina
HTG Molecular Diagnostics HTG Molecular Diagnostics
HTGM
- -20.0 % $ 1.06 M usaUSA
Castle Biosciences Castle Biosciences
CSTL
$ 23.53 -4.74 % $ 654 M usaUSA
PRA Health Sciences, Inc. PRA Health Sciences, Inc.
PRAH
- - $ 10.7 B usaUSA
Charles River Laboratories International Charles River Laboratories International
CRL
$ 159.16 -3.62 % $ 7.89 B usaUSA
Quest Diagnostics Incorporated Quest Diagnostics Incorporated
DGX
$ 195.51 -1.33 % $ 21.7 B usaUSA
Organovo Holdings Organovo Holdings
ONVO
- -2.3 % $ 19.4 M usaUSA
OpGen OpGen
OPGN
- -16.95 % $ 1.54 M usaUSA
Biocept Biocept
BIOC
- -13.05 % $ 7.29 M usaUSA
PerkinElmer PerkinElmer
PKI
- -0.91 % $ 14.7 B usaUSA
Invitae Corporation Invitae Corporation
NVTA
- - $ 21.2 M usaUSA
Interpace Biosciences Interpace Biosciences
IDXG
$ 1.68 -2.89 % $ 7.37 M usaUSA
Motus GI Holdings Motus GI Holdings
MOTS
- -34.28 % $ 263 K israelIsrael
QIAGEN N.V. QIAGEN N.V.
QGEN
- - $ 10.6 B niderlandNiderland
Neogen Corporation Neogen Corporation
NEOG
$ 8.7 -4.92 % $ 1.89 B usaUSA
Chembio Diagnostics Chembio Diagnostics
CEMI
- 0.22 % $ 16.8 M usaUSA
Laboratory Corporation of America Holdings Laboratory Corporation of America Holdings
LH
$ 264.2 -1.56 % $ 22 B usaUSA
Psychemedics Corporation Psychemedics Corporation
PMD
- -1.84 % $ 15.3 M usaUSA
Precipio Precipio
PRPO
$ 25.97 -4.52 % $ 33.7 M usaUSA
CareDx, Inc CareDx, Inc
CDNA
$ 16.78 -3.95 % $ 894 M usaUSA
Quotient Limited Quotient Limited
QTNT
- -11.32 % $ 1.1 M schweizSchweiz
Syneos Health Syneos Health
SYNH
- - $ 4.46 B usaUSA
Renalytix AI plc Renalytix AI plc
RNLX
- 5.66 % $ 22.7 M britainBritain
VolitionRx Limited VolitionRx Limited
VNRX
$ 0.2 1.87 % $ 19.2 M singaporeSingapore
Bioventus Bioventus
BVS
$ 8.94 -3.46 % $ 596 M usaUSA
Co-Diagnostics Co-Diagnostics
CODX
$ 4.4 101.83 % $ 129 M usaUSA
Meridian Bioscience Meridian Bioscience
VIVO
- - $ 1.49 B usaUSA
Danaher Corporation Danaher Corporation
DHR
$ 181.52 -3.27 % $ 129 B usaUSA
Surmodics Surmodics
SRDX
- - $ 608 M usaUSA
ENDRA Life Sciences ENDRA Life Sciences
NDRA
$ 4.29 -6.54 % $ 2.3 M usaUSA